{"entity":{"edinet_code":"E02608","sec_code":"8129","name_ja":"東邦ホールディングス株式会社","name_en":"TOHO HOLDINGS CO.,LTD.","industry":"卸売業","industry_en":"Wholesale Trade"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YHSN","filer_name":"東邦ホールディングス株式会社","filer_name_en":"TOHO HOLDINGS CO.,LTD.","period_end":"2026-03-31","filed_date":"2026-06-24","sha256":"84303d60d3a79555aec10515fe62ecacb73068990ae9f16a5d27975c7df69a39","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"大塚ホールディングス㈱","held_name_en":"Otsuka Holdings Co., Ltd.","held_sec_code":"4578","match_status":"matched","shares":1400000,"book_value_yen":15414000000,"prior_shares":2000000,"prior_book_value_yen":15506000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.26508553646601185,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":5.6760936809544855,"pct_of_holder_assets":2.0807769097749538,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"塩野義製薬㈱","held_name_en":"Shionogi & Co., Ltd.","held_sec_code":"4507","match_status":"matched","shares":1570842,"book_value_yen":5449000000,"prior_shares":1570842,"prior_book_value_yen":3528000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.1826612512953058,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.006554720871999,"pct_of_holder_assets":0.7355750214975816,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"大木ヘルスケアホールディングス㈱","held_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","held_sec_code":"3417","match_status":"matched","shares":1413000,"book_value_yen":1880000000,"prior_shares":1413000,"prior_book_value_yen":1131000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":10.360756709194897,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6922963617616733,"pct_of_holder_assets":0.2537862067196648,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"第一三共 ㈱  ","held_name_en":"DAIICHI SANKYO COMPANY, LIMITED","held_sec_code":"4568","match_status":"matched","shares":524900,"book_value_yen":1451000000,"prior_shares":524900,"prior_book_value_yen":1842000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.02862319806900413,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5343202238915893,"pct_of_holder_assets":0.19587435422884766,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":428920,"book_value_yen":1076000000,"prior_shares":1177920,"prior_book_value_yen":1887000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.08967486693133701,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3962291942848726,"pct_of_holder_assets":0.14525210554806348,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ツムラ","held_name_en":"TSUMURA & CO.","held_sec_code":"4540","match_status":"matched","shares":227300,"book_value_yen":851000000,"prior_shares":227300,"prior_book_value_yen":980000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.30190789585710376,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.31337457652084255,"pct_of_holder_assets":0.11487875633959295,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"明治ホールディングス㈱","held_name_en":"Meiji Holdings Co.,Ltd.","held_sec_code":"2269","match_status":"matched","shares":163018,"book_value_yen":629000000,"prior_shares":162481,"prior_book_value_yen":528000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため持株会による取得のため株式数が増加  ","reciprocal":"有","pct_outstanding":0.06013161098036901,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.23162468699366623,"pct_of_holder_assets":0.0849103851205687,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本新薬㈱  ","held_name_en":"Nippon Shinyaku Co., Ltd.","held_sec_code":"4516","match_status":"matched","shares":96959,"book_value_yen":495000000,"prior_shares":96959,"prior_book_value_yen":368000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.1438539829032763,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18228015908086612,"pct_of_holder_assets":0.06682136825863515,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":102025,"book_value_yen":474000000,"prior_shares":98176,"prior_book_value_yen":377000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため持株会による取得のため株式数が増加","reciprocal":"有","pct_outstanding":0.24612754702206174,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17454706142288998,"pct_of_holder_assets":0.06398652233251123,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"杏林製薬㈱","held_name_en":"KYORIN Pharmaceutical Co., Ltd.","held_sec_code":"4569","match_status":"matched","shares":205000,"book_value_yen":337000000,"prior_shares":205000,"prior_book_value_yen":307000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.3528062839996619,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.12409780527323612,"pct_of_holder_assets":0.0454925274811314,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"持田製薬㈱","held_name_en":"Mochida Pharmaceutical Co.,Ltd.","held_sec_code":"4534","match_status":"matched","shares":88468,"book_value_yen":306000000,"prior_shares":88468,"prior_book_value_yen":281000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.2495592346338615,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.11268228015908087,"pct_of_holder_assets":0.04130775492351991,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ゼリア新薬工業㈱","held_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","held_sec_code":"4559","match_status":"matched","shares":101374,"book_value_yen":222000000,"prior_shares":101374,"prior_book_value_yen":228000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.22997997481368318,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08174988952717631,"pct_of_holder_assets":0.029968371219024247,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱メディカル一光グループ","held_name_en":"Medical Ikkou Group Co.,Ltd.","held_sec_code":"3353","match_status":"matched","shares":73000,"book_value_yen":206000000,"prior_shares":203000,"prior_book_value_yen":474000000,"purpose_ja":"医薬品の販売等の取引において良好な取引関係の維持、強化のため","reciprocal":"無","pct_outstanding":1.9384476486364481,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.07585800559728974,"pct_of_holder_assets":0.02780848860864412,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱アドバンスト・メディア","held_name_en":"Advanced Media, Inc.","held_sec_code":"3773","match_status":"matched","shares":162000,"book_value_yen":184000000,"prior_shares":162000,"prior_book_value_yen":140000000,"purpose_ja":"同上","reciprocal":"無","pct_outstanding":1.0344547503950086,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06775666519369568,"pct_of_holder_assets":0.024838650019371446,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小林製薬㈱","held_name_en":"KOBAYASHI PHARMACEUTICAL CO.,LTD.","held_sec_code":"4967","match_status":"matched","shares":16832,"book_value_yen":99000000,"prior_shares":16615,"prior_book_value_yen":94000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため持株会による取得のため株式数が増加","reciprocal":"有","pct_outstanding":0.022642281016104646,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.03645603181617322,"pct_of_holder_assets":0.01336427365172703,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"扶桑薬品工業㈱","held_name_en":"Fuso Pharmaceutical Industries, Ltd.","held_sec_code":"4538","match_status":"matched","shares":40083,"book_value_yen":94000000,"prior_shares":40083,"prior_book_value_yen":97000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.46951711412898267,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.034614818088083664,"pct_of_holder_assets":0.01268931033598324,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":100766,"book_value_yen":92000000,"prior_shares":100766,"prior_book_value_yen":89000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.4901976046156391,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03387833259684784,"pct_of_holder_assets":0.012419325009685723,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ビー・エム・エル","held_name_en":"BML, INC.","held_sec_code":"4694","match_status":"matched","shares":13000,"book_value_yen":52000000,"prior_shares":13000,"prior_book_value_yen":39000000,"purpose_ja":"医薬品の販売等の取引において良好な取引関係の維持、強化のため","reciprocal":"無","pct_outstanding":0.03468181013224281,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.01914862277213139,"pct_of_holder_assets":0.007019618483735409,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"シップヘルスケアホールディングス㈱","held_name_en":"SHIP HEALTHCARE HOLDINGS,INC.","held_sec_code":"3360","match_status":"matched","shares":20000,"book_value_yen":47000000,"prior_shares":20000,"prior_book_value_yen":40000000,"purpose_ja":"同上","reciprocal":"無","pct_outstanding":0.02173465734780192,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.017307409044041832,"pct_of_holder_assets":0.00634465516799162,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"シスメックス㈱","held_name_en":"SYSMEX CORPORATION","held_sec_code":"6869","match_status":"matched","shares":32400,"book_value_yen":44000000,"prior_shares":32400,"prior_book_value_yen":91000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"無","pct_outstanding":0.005172076287052507,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.016202680807188098,"pct_of_holder_assets":0.005939677178545346,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"科研製薬㈱","held_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4521","match_status":"matched","shares":6567,"book_value_yen":27000000,"prior_shares":6567,"prior_book_value_yen":29000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.017250695662475835,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.009942554131683606,"pct_of_holder_assets":0.0036448019050164624,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"クリングルファーマ㈱","held_name_en":"Ｋｒｉｎｇｌｅ　Ｐｈａｒｍａ，　Ｉｎｃ．","held_sec_code":"4884","match_status":"matched","shares":66660,"book_value_yen":27000000,"prior_shares":66660,"prior_book_value_yen":58000000,"purpose_ja":"同上","reciprocal":"無","pct_outstanding":0.949829725994215,"pct_unavailable":null,"pct_basis_period_end":"2025-09-30","pct_share_classes":1,"pct_of_holder_equity":0.009942554131683606,"pct_of_holder_assets":0.0036448019050164624,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ジェイ・エム・エス","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":49396,"book_value_yen":20000000,"prior_shares":45786,"prior_book_value_yen":21000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため持株会による取得のため株式数が増加","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.007364854912358227,"pct_of_holder_assets":0.002699853262975157,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本ケミファ㈱","held_name_en":"NIPPON CHEMIPHAR CO., LTD.","held_sec_code":"4539","match_status":"matched","shares":4329,"book_value_yen":7000000,"prior_shares":4329,"prior_book_value_yen":6000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.11856635772037073,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.002577699219325379,"pct_of_holder_assets":0.000944948642041305,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"サッポロホールディングス㈱","held_name_en":"SAPPORO HOLDINGS LIMITED","held_sec_code":"2501","match_status":"matched","shares":500,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"情報収集のため 株式分割のため株式数が増加","reciprocal":"無","pct_outstanding":null,"pct_unavailable":"holding restated onto a share base the issuer has not filed yet","pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share split"],"note_refs":[],"share_ratio":5.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":4.885230259612567e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱スズケン","held_name_en":"SUZUKEN CO.,LTD.","held_sec_code":"9987","match_status":"matched","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.0001478460952900019,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アルフレッサホールディングス㈱","held_name_en":"Alfresa Holdings Corporation","held_sec_code":"2784","match_status":"matched","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":5.488404921342925e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ソラスト","held_name_en":"Solasto Corporation","held_sec_code":"6197","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":4709500,"prior_book_value_yen":2156000000,"purpose_ja":"同社との連携を強化し、地域包括ケアの推進に貢献していくため","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"エーザイ㈱","held_name_en":"Eisai Co., Ltd.","held_sec_code":"4523","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":9300,"prior_book_value_yen":38000000,"purpose_ja":"同上","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"住友ファーマ㈱","held_name_en":"Sumitomo Pharma Co., Ltd.","held_sec_code":"4506","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":77086,"prior_book_value_yen":56000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"テルモ㈱","held_name_en":"TERUMO CORPORATION","held_sec_code":"4543","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":337800,"prior_book_value_yen":944000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"参天製薬㈱  ","held_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4536","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":567950,"prior_book_value_yen":805000000,"purpose_ja":"同上","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ウエルシアホールディングス㈱","held_name_en":"WELCIA HOLDINGS CO., LTD.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":61461,"prior_book_value_yen":132000000,"purpose_ja":"医薬品の販売等の取引において良好な取引関係の維持、強化のため","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"久光製薬㈱  ","held_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":93581,"prior_book_value_yen":378000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"塩野義製薬株式会社","holder_name_en":"Shionogi & Co., Ltd.","holder_sec_code":"4507","doc_id":"S100Z43Z","period_end":"2026-03-31","holder_table":"reporting","shares":3500112,"book_value_yen":16667000000,"prior_shares":3500112,"prior_book_value_yen":15610000000,"purpose_ja":"同社グループは当社の取引先の一つであるため、医薬品販売等における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":5.41149198996488,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9890132713036616,"pct_of_holder_assets":0.6467924264708735,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"田辺三菱製薬株式会社","holder_name_en":"Mitsubishi Tanabe Pharma Corporation","holder_sec_code":"4508","doc_id":"S100G3TB","period_end":"2019-03-31","holder_table":"reporting","shares":3573456,"book_value_yen":9873000000,"prior_shares":3573456,"prior_book_value_yen":8955000000,"purpose_ja":null,"reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":1.099928253439156,"pct_of_holder_assets":0.934690036599936,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":897604000000,"holder_total_assets_yen":1056286000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大塚ホールディングス株式会社","holder_name_en":"Otsuka Holdings Co., Ltd.","holder_sec_code":"4578","doc_id":"S100XUA7","period_end":"2025-12-31","holder_table":"largest","shares":789800,"book_value_yen":3686000000,"prior_shares":789800,"prior_book_value_yen":3372000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":1.2211027457619246,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.12151205032959238,"pct_of_holder_assets":0.08781287804682814,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"小野薬品工業株式会社","holder_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","holder_sec_code":"4528","doc_id":"S100YOIE","period_end":"2026-03-31","holder_table":"reporting","shares":399350,"book_value_yen":1902000000,"prior_shares":399350,"prior_book_value_yen":1781000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.6174314782476888,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2235734847959451,"pct_of_holder_assets":0.1718910272341541,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大正製薬ホールディングス株式会社","holder_name_en":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","holder_sec_code":"4581","doc_id":"S100R80T","period_end":"2023-03-31","holder_table":"reporting","shares":762000,"book_value_yen":1791000000,"prior_shares":762000,"prior_book_value_yen":1409000000,"purpose_ja":"当社医薬事業における販売取引関係の維持・強化のために保有しています。","reciprocal":"有","pct_outstanding":1.1382454009881702,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":0.22129060237748396,"pct_of_holder_assets":0.19023037950482746,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":809343000000,"holder_total_assets_yen":941490000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"杏林製薬株式会社","holder_name_en":"KYORIN Pharmaceutical Co., Ltd.","holder_sec_code":"4569","doc_id":"S100YDHG","period_end":"2026-03-31","holder_table":"reporting","shares":374980,"book_value_yen":1785000000,"prior_shares":374980,"prior_book_value_yen":1672000000,"purpose_ja":"医薬品の安定供給を図るため、同社の充実した販売網を経常的に活用するために保有するものであり、当社の持続成長や企業価値向上の観点から総合的に保有の適否を検証しております","reciprocal":"有","pct_outstanding":0.579753238295526,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.253291205897841,"pct_of_holder_assets":0.9132536901076974,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":142425000000,"holder_total_assets_yen":195455000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大木ヘルスケアホールディングス株式会社","holder_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","holder_sec_code":"3417","doc_id":"S100YF0K","period_end":"2026-03-31","holder_table":"largest","shares":372000,"book_value_yen":1771000000,"prior_shares":372000,"prior_book_value_yen":1659000000,"purpose_ja":"・同社株式は、当社グループの事業活動の円滑化のため保有しております。・同社グループは、当社グループにおける業務提携先であると共に、販売先及び仕入先であり、当社の事業継続に不可欠な取引先であります。・当社グループは保有株式について、配当・取引額に加え、経営戦略上の重要性や事業上の関係等を総合的に判断し、保有の便益とリスクの見合いを勘案し保有しております。定量的な保有効果については、取引先との関係性を考慮し記載しませんが、上記方針に基づいて総合的に保有効果を判断しております。 ","reciprocal":"有","pct_outstanding":0.5751458868364598,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":5.183515775917579,"pct_of_holder_assets":1.1934525213453464,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":34166000000,"holder_total_assets_yen":148393000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":356581,"book_value_yen":1698000000,"prior_shares":356581,"prior_book_value_yen":1590000000,"purpose_ja":"同社は医薬品事業における取引先の一つであるため、取引関係維持・強化のために株式を保有しています。具体的には、医療用医薬品の販売先です。2026年４月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しています。","reciprocal":"有","pct_outstanding":0.551306708263526,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7333632782806994,"pct_of_holder_assets":0.617261510945668,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本新薬株式会社","holder_name_en":"Nippon Shinyaku Co., Ltd.","holder_sec_code":"4516","doc_id":"S100YGRG","period_end":"2026-03-31","holder_table":"reporting","shares":325453,"book_value_yen":1549000000,"prior_shares":325453,"prior_book_value_yen":1451000000,"purpose_ja":"医薬品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.503179984700501,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5312964112625236,"pct_of_holder_assets":0.44722383422980205,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ツムラ","holder_name_en":"TSUMURA & CO.","holder_sec_code":"4540","doc_id":"S100YFC1","period_end":"2026-03-31","holder_table":"reporting","shares":280218,"book_value_yen":1334000000,"prior_shares":280218,"prior_book_value_yen":1249000000,"purpose_ja":"医薬品販売等の取引関係を維持・強化し、中長期的な企業価値の向上のため保有しており、当社の資本コストと配当金・取引額の比較等により、当社に便益があることを確認しています。","reciprocal":"有","pct_outstanding":0.4332425540794062,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.35898526115235885,"pct_of_holder_assets":0.22504664572529465,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":371603000000,"holder_total_assets_yen":592766000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ほくやく・竹山ホールディングス","holder_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","holder_sec_code":"3055","doc_id":"S100YJPG","period_end":"2026-03-31","holder_table":"largest","shares":260800,"book_value_yen":1241000000,"prior_shares":260800,"prior_book_value_yen":1163000000,"purpose_ja":"（保有目的）業界動向把握のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.40322055722298045,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.9191809844888112,"pct_of_holder_assets":0.797122394578797,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"持田製薬株式会社","holder_name_en":"Mochida Pharmaceutical Co.,Ltd.","holder_sec_code":"4534","doc_id":"S100YI28","period_end":"2026-03-31","holder_table":"reporting","shares":243400,"book_value_yen":1159000000,"prior_shares":243400,"prior_book_value_yen":1085000000,"purpose_ja":"取引関係の維持・強化のため、保有しております。保有効果を定量的に量りかねるため、取引関係への影響を含む現在及び将来の意義を総合的に判断のうえ、保有の適否を取締役会において、検証しました。なお、同社子会社と医薬品販売等の重要な取引を行っております。","reciprocal":"有","pct_outstanding":0.37631857219353315,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8259338967832048,"pct_of_holder_assets":0.6343038528896673,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":140326000000,"holder_total_assets_yen":182720000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"小林製薬株式会社","holder_name_en":"KOBAYASHI PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4967","doc_id":"S100XSXS","period_end":"2025-12-31","holder_table":"reporting","shares":186500,"book_value_yen":870000000,"prior_shares":186500,"prior_book_value_yen":796000000,"purpose_ja":"当社製品の主要代理店であり、協力関係を維持していくために保有しております。","reciprocal":"有","pct_outstanding":0.2883459889650531,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4123066424021838,"pct_of_holder_assets":0.3159856026789768,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":211008000000,"holder_total_assets_yen":275329000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"テルモ株式会社","holder_name_en":"TERUMO CORPORATION","holder_sec_code":"4543","doc_id":"S100YGMG","period_end":"2026-03-31","holder_table":"reporting","shares":122080,"book_value_yen":581000000,"prior_shares":122080,"prior_book_value_yen":544000000,"purpose_ja":"主にメディカルケアソリューションズカンパニーにおける代理店取引関係維持・強化のため保有しております。 ","reciprocal":"無","pct_outstanding":0.1887468007123522,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.036667510250809554,"pct_of_holder_assets":0.025127214633121044,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1584509000000,"holder_total_assets_yen":2312234000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"扶桑薬品工業株式会社","holder_name_en":"Fuso Pharmaceutical Industries, Ltd.","holder_sec_code":"4538","doc_id":"S100YHSC","period_end":"2026-03-31","holder_table":"reporting","shares":94000,"book_value_yen":447000000,"prior_shares":94000,"prior_book_value_yen":419000000,"purpose_ja":"・製商品の販売を行う取引先企業との業務　のより円滑な推進・株価の評価益及び受取配当金の発生","reciprocal":"有","pct_outstanding":0.14533256280276136,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.2750663205636534,"pct_of_holder_assets":0.4948905594366883,"holder_equity_basis":"parent_only","holder_equity_yen":35057000000,"holder_total_assets_yen":90323000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本化薬株式会社","holder_name_en":"NIPPON KAYAKU CO.,LTD.","holder_sec_code":"4272","doc_id":"S100YD4R","period_end":"2026-03-31","holder_table":"reporting","shares":83200,"book_value_yen":396000000,"prior_shares":83200,"prior_book_value_yen":371000000,"purpose_ja":"（保有目的）ライフサイエンス事業領域における販売先として関係の維持、強化を図るため（定量的な保有効果）　（注）1","reciprocal":"無","pct_outstanding":0.12863477899138026,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1413760603204524,"pct_of_holder_assets":0.09931383170819791,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":280104000000,"holder_total_assets_yen":398736000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":82962,"book_value_yen":347000000,"prior_shares":82962,"prior_book_value_yen":262000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.1325679391912611,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1241915914776652,"pct_of_holder_assets":0.10114612846432777,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"科研製薬株式会社","holder_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4521","doc_id":"S100YK2Q","period_end":"2026-03-31","holder_table":"reporting","shares":40750,"book_value_yen":194000000,"prior_shares":40750,"prior_book_value_yen":181000000,"purpose_ja":"医薬品販売に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。","reciprocal":"有","pct_outstanding":0.06300321206609069,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1314193972320636,"pct_of_holder_assets":0.10885605750293181,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":147619000000,"holder_total_assets_yen":178217000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キムラユニティー株式会社","holder_name_en":"KIMURA UNITY CO.,LTD.","holder_sec_code":"9368","doc_id":"S100YCXZ","period_end":"2026-03-31","holder_table":"reporting","shares":27525,"book_value_yen":131000000,"prior_shares":27525,"prior_book_value_yen":122000000,"purpose_ja":"保有目的は、取引維持や強化のためです。業務提携等は、ありません。定量的な保有効果は、コーポレートガバナンスコードの基準にて、収益の増加や株式保有コストなどの経済的合理性の適否を評価し、保有するのが妥当と判断しております。","reciprocal":"無","pct_outstanding":0.042556157352617086,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.28292514362230575,"pct_of_holder_assets":0.1836251244025175,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":46302000000,"holder_total_assets_yen":71341000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"日本ケミファ株式会社","holder_name_en":"NIPPON CHEMIPHAR CO., LTD.","holder_sec_code":"4539","doc_id":"S100YBOB","period_end":"2026-03-31","holder_table":"reporting","shares":7890,"book_value_yen":37000000,"prior_shares":7890,"prior_book_value_yen":35000000,"purpose_ja":"（保有目的）医薬品事業における取引先であり、良好な取引関係の維持・強化を図るため（定量的な保有効果）（注）２","reciprocal":"有","pct_outstanding":0.012198658728870075,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18964633521271143,"pct_of_holder_assets":0.0740325743327064,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":19510000000,"holder_total_assets_yen":49978000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日医工株式会社","holder_name_en":"Nichi-Iko Pharmaceutical Co., Ltd.","holder_sec_code":"4541","doc_id":"S100OLZH","period_end":"2022-03-31","holder_table":"reporting","shares":19291,"book_value_yen":35000000,"prior_shares":17341,"prior_book_value_yen":35000000,"purpose_ja":"(保有目的)当社の販売先である医薬品卸であり、販売協力関係構築を目的として保有しております。(株式数が増加した理由)販売協力関係の強化を目的とした株式取得(取引先持株会を通じた株式取得)。","reciprocal":"有","pct_outstanding":0.02735600335016385,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.26131103479169776,"pct_of_holder_assets":0.013432658246308897,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":13394000000,"holder_total_assets_yen":260559000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大宝運輸株式会社","holder_name_en":"Taiho Transportation Co., Ltd.","holder_sec_code":"9040","doc_id":"S100YADW","period_end":"2026-03-20","holder_table":"reporting","shares":7500,"book_value_yen":34372000,"prior_shares":7500,"prior_book_value_yen":32385000,"purpose_ja":"地域経済発展を担う地元企業との関係の維持強化のため","reciprocal":"無","pct_outstanding":0.011595683202347981,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5030506188465137,"pct_of_holder_assets":0.34880647035393625,"holder_equity_basis":"parent_only","holder_equity_yen":6832712000,"holder_total_assets_yen":9854175000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社大本組","holder_name_en":"OHMOTO GUMI CO., LTD.","holder_sec_code":"1793","doc_id":"S100YI8J","period_end":"2026-03-31","holder_table":"reporting","shares":2700,"book_value_yen":12000000,"prior_shares":2700,"prior_book_value_yen":12000000,"purpose_ja":"主要発注者として同社より工事を受注しております。今後も継続して保有することにより、良好な関係の維持・強化を通じて、当社の中長期的な企業価値の向上を図ることを目的としております。","reciprocal":"無","pct_outstanding":0.004174445952845273,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.017467248908296942,"pct_of_holder_assets":0.011585919246142854,"holder_equity_basis":"parent_only","holder_equity_yen":68700000000,"holder_total_assets_yen":103574000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":1000,"book_value_yen":4000000,"prior_shares":1000,"prior_book_value_yen":4000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.0015460910936463974,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0005028922591051786,"pct_of_holder_assets":0.00020811632870309187,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ゼリア新薬工業株式会社","holder_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","holder_sec_code":"4559","doc_id":"S100YKC2","period_end":"2026-03-31","holder_table":"reporting","shares":126,"book_value_yen":600000,"prior_shares":126,"prior_book_value_yen":561000,"purpose_ja":"（保有目的）医療用医薬品事業活動の円滑な推進（定量的な保有効果）（注）１","reciprocal":"有","pct_outstanding":0.00019480747779944608,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0005524618205145464,"pct_of_holder_assets":0.0003338936272444601,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":108604790000,"holder_total_assets_yen":179697949000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"・同業界内における関係維持発展に伴う中　長期的な企業価値の向上・当社グループの取引先・検証実施(注)１","reciprocal":"有","pct_outstanding":0.00015460910936463974,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"largest","shares":null,"book_value_yen":null,"prior_shares":250000,"prior_book_value_yen":1115000000,"purpose_ja":"①同業者としての情報収集のため　②該当なし　③当事業年度中に売却したため、保有効果の検証はしておりません　④該当なし","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"参天製薬株式会社","holder_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4536","doc_id":"S100YDH1","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":69050,"prior_book_value_yen":308000000,"purpose_ja":"当社医薬品等の販売契約があり、眼科領域における事業関係の強化を図ることを目的に保有していましたが、当事業年度において全株式を売却しました。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":296989000000,"holder_total_assets_yen":423033000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"reporting","note_no":"1","text_ja":"（注）１．当該投資株式の銘柄数が60に満たないため、貸借対照表計上額が資本金額の100分の１以下である銘柄を含めて記載しております。"},{"holder_table":"reporting","note_no":"2","text_ja":"２.「―」は、当該銘柄を保有していないことを示しております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":4,"acquisition_cost_yen":21000000,"issues_decreased":10,"sale_proceeds_yen":14282000000,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":4,"acquisition_cost_yen":849000000,"issues_decreased":1,"sale_proceeds_yen":0,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":37552000000,"listed_yen":29496000000,"unlisted_yen":8056000000,"listed_issues":28,"unlisted_issues":43,"equity_yen":271560000000,"equity_basis":"jgaap_consolidated","total_assets_yen":740781000000,"assets_basis":"jgaap_consolidated","pct_of_equity":13.828251583443807,"pct_of_assets":5.069244486562155,"equity_basis_label":"Consolidated net assets (Japanese GAAP)","assets_basis_label":"Consolidated net assets (Japanese GAAP)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":29496000000,"issue_count":28,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":8056000000,"issue_count":43,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":55900000000,"equity_yen":241281000000,"equity_basis":"jgaap_consolidated","pct_of_equity":23.16800742702492,"pct_of_assets":7.958700183377564},{"year":"2023","period_end":"2023-03-31","policy_total_yen":50368000000,"equity_yen":242916000000,"equity_basis":"jgaap_consolidated","pct_of_equity":20.734739580760426,"pct_of_assets":7.04163917191397},{"year":"2024","period_end":"2024-03-31","policy_total_yen":48764000000,"equity_yen":249437000000,"equity_basis":"jgaap_consolidated","pct_of_equity":19.549625757205227,"pct_of_assets":6.304925998187288},{"year":"2025","period_end":"2025-03-31","policy_total_yen":41583000000,"equity_yen":256897000000,"equity_basis":"jgaap_consolidated","pct_of_equity":16.18664289579092,"pct_of_assets":5.753003922219686},{"year":"2026","period_end":"2026-03-31","policy_total_yen":37552000000,"equity_yen":271560000000,"equity_basis":"jgaap_consolidated","pct_of_equity":13.828251583443807,"pct_of_assets":5.069244486562155}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2022","period_end":"2022-03-31","named_holdings":60,"book_value_yen":48079000000},{"year":"2023","period_end":"2023-03-31","named_holdings":47,"book_value_yen":42545000000},{"year":"2024","period_end":"2024-03-31","named_holdings":38,"book_value_yen":39074000000},{"year":"2025","period_end":"2025-03-31","named_holdings":36,"book_value_yen":32650000000},{"year":"2026","period_end":"2026-03-31","named_holdings":35,"book_value_yen":29483000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}